Ascendis Pharma (ASND) Tops Q1 EPS by 68c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR1.98), EUR0.68 better than the analyst estimate of (EUR2.66). Revenue for the quarter came in at EUR28.97 million versus the consensus estimate of EUR21.15 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)
• UBS Reiterates Neutral Rating on Yeti Holdings Inc. (YETI) Ahead of Analyst Meeting
• Ascendis Pharma reports 52-week infant data for TransCon CNP trial